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Abstract Objective: The objective of this study was to investigate the safety and
pharmacokinetics of edaravone administered by single or successive intra-
venous infusions in healthy Chinese volunteers.
Methods: A total of 30 subjects (15 males and 15 females) were recruited and
randomly assigned to three groups receiving edaravone doses of 20, 30, and
60mg. All subjects received a single dose of edaravone during a 30-minute
period, and only the 30mg dose group continued to receive the same dose
successively by intravenous infusion twice daily for the next 5 days. Plasma
concentrations of edaravone were monitored by high-performance liquid
chromatography at the following times: 15, 30, 45, 60, 75, 105, 165, 225, 300,
390, 480, 600, and 720 minutes after edaravone administration.
Results: The area under the plasma concentration-time curve during a dosage
interval (AUCt) values of the single dose in the 20, 30, and 60mg dose groups
were 3.64– 1.37, 5.17 – 0.93, and 11.25– 3.42mgh/L, respectively, while
in the group receiving repeated dosing of 30mg, the mean AUCt value was
5.06– 0.89mgh/L. The corresponding maximum plasma drug concentration
(Cmax) values were 1599.0– 382.6, 2378.7– 316.7, and 4540.1– 901.1 ng/mL,
respectively, in the single-dose groups, and 2479.1– 477.9 ng/mL in the 30mg
repeated-dose group. ThemeanAUCt andCmax ratios between the repeated-dose
group and the single-dose groups were 0.98 and 1.04. All laboratory test abnor-
malities (including increased alanine transaminase and triacylglycerol levels, and
decreased white blood cell counts and creatinine levels) were mild and tolerable.
All abnormal blood biochemical indices returned to normal levels after 7 days.
Conclusion: Edaravone was safe and well tolerated in the volunteers and
displayed linear increases in the Cmax and AUCt values.
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Introduction
Free radicals have been considered one of the
most harmful factors that contribute to the devel-
opment of cardiovascular disease, cancer, neuro-
degenerative disease, etc.[1-5] The term ‘free-radical
scavengers’ refers to chemicals (such as vitamins,
minerals, or enzymes) that are able to destroy free
radicals. Although many free-radical scavengers
are utilized clinically, only a few of them (such as
NXY-059, 21-aminosteroid tirilazad, and edar-
avone [3-methyl-1-phenyl-2-pyrazolin-5-one; see
figure 1]) have been used in the conduct of clinical
trials in ischemic stroke.[6] Among those, edar-
avone is widely utilized in clinical trials to protect
tissues from ischemia reperfusion injury after acute
ischemic stroke.[7-9]
Edaravone can scavenge both hydroxyl radi-
cals and peroxynitrite radicals, but it has no sig-
nificant effect on superoxide anion radicals.[10,11]
According to recent reports, edaravone has vari-
ous functions, such as relieving neuropathic pain
induced by spinal nerves,[10] attenuating nerve injury
induced by ischemia,[12] elevating the metabolism
rate,[13] reducing the inflammatory response,[14]
and ameliorating experimental autoimmune en-
cephalomyelitis.[15] Edaravone can be useful for
the treatment of diseases and clinical conditions
in which oxidative stress plays a key role in the
pathogenesis.[16] Some studies have also indicated
that edaravone shows beneficial effects in treat-
ment of idiopathic sudden sensorineural hearing
loss with profound hearing-loss encephalomyeli-
tis.[17] The major side effects of edaravone are hep-
atic impairment or renal function disorder.[18] For
that reason, it is prescribed with care to patients
who have a clinical history of hepatic or renal
disorder.
A few analytical methods of measuring edar-
avone plasma concentrations have been reported,
such as liquid chromatography with tandemmass
spectrometry (LC-MS/MS) and gas chromatog-
raphywithmass spectrometry (GC-MS).[19,20] These
two methods are feasible but have their limi-
tations. The objective of this studywas to investigate
the safety and pharmacokinetics of edaravone
administered by single or successive intravenous
infusions in healthy Chinese volunteers.
Materials and Methods
Design and Demographic Characteristics
The protocol was approved in advance by the
hospital ethics committee and conducted in ac-
cordance with Good Clinical Practice and the
Helsinki Declaration. After receiving oral and
written explanations of the study, the subjects
gave written informed consent prior to starting
the study. All subjects (15 males and 15 females)
were recruited into three edaravone dose groups
(20, 30, and 60mg). The volunteers who had been
given a 30mg single dose continued to receive
multiple administrations from the second day,
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Fig. 1. Chemical structure of edaravone (3-methyl-1-phenyl-2-
pyrazolin-5-one; MCI-185).
Table I. Demographic characteristics of the subjects
Characteristic Edaravone dose
20mg 30mg 60mg
Subjects (n) 10 10 10
Sex (n; male/female) 5/5 5/5 5/5
Age (years)a 39.9 – 1.7 [36–42] 31.2 –3.1 [27–35] 23.0 – 2.6 [20–29]
Weight (kg)a 59.7 – 11.0 [46–75] 62.6 –7.6 [52–74] 64.4 – 7.6 [50–78]
Height (cm)a 165.3 – 9.1 [153–177] 167.4 –7.2 [158–177] 170.3 – 7.0 [159–181]
Body mass index (kg/m2)a 21.6 – 2.0 [18.8–23.9] 22.3 –1.3 [20.8–23.9] 22.1 – 1.3 [19.5–23.8]
a Values are given as means – standard deviations, with ranges in brackets.
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twice daily for 5 days. None of the subjects con-
sumed excessive amounts of alcohol or smoked,
and none took any drugs during or at least 1 week
prior to the study. Subjects were excluded on the
basis of a clinically significantly abnormal elec-
trocardiogram, the results of blood chemistry or
urinalysis tests, or a positive result on the pregnancy
test. The demographic characteristics of the study
cohort are presented in table I. The subjects fasted
from 10 hours before to 2 hours after edaravone
administration. The volunteers were observed for
24 hours post-drug administration, during which
time both safety laboratory data and the results
of physical examinations were assessed. The
edaravone parenteral solution was provided by
Yangtze River Pharmaceutical Group–Nanjing
Hailing Pharmaceutical Co. Ltd. (Nanjing, China).
Sample Collection and Assays of Edaravone
Peripheral blood samples were drawn from an
intravenous cannula (inserted into a forearm vein)
into 5mL heparinized tubes prior to and after
intravenous administration of edaravone at the
following times: 5, 10, 15, 30, 45, 60, 120, 180, 240,
360, 480, 600, and 720 minutes. After collection,
the blood samples were immediately centrifuged
at 3500 rpm for 6 minutes, and the plasma was
separated and stored at -80C until analysis. The
plasma concentrations were measured by HPLC
with an ultraviolet (UV) detector (LC-2010-CTH;
Shimadzu,Kyoto, Japan). The assay was performed
in accordance with the following procedure. An
aliquot of 0.2mL of plasma was vortex mixed
with 40 mL of HClO4 (30%) to acidify the plasma
and precipitate plasma protein for 40 seconds,
then centrifuged at 4C at 16000 rpm for 6 minutes.
The supernate fluid was then prepared for analysis.
An aliquot of 20 mL of the supernate fluid was
analyzed using a Syncronis C18 column (250mm·
4.6mm; 5mm) [Thermo Scientific, Waltham, MA,
USA]. The mobile phase consisted of ammonium
acetate buffer (pH 6.6; 0.05mol/L) and methanol
[Merck, Darmstadt, Germany] (55 : 45, v/v). The
flow rate was 1.0mL/min; the detector wave was
set at 240 nm. The limit of quantification was
30 ng/mL, and the intra- and inter-batch relative
standard deviations were less than 9% and 13%,
respectively.
Table II. Pharmacokinetic parameters on the first day after a single 30-minute intravenous infusion of edaravone in the three dose groups,
and on the fifth day after repeated twice daily doses in the 30mg dose group (n= 10)
Dose group AUCt
(mgh/L)a AUC¥(mgh/L)a Cmax(mg/mL)a t½(h)a CL(L/min)a Vd(L/kg)a
20mg Single dose 3.64 – 1.37 3.79 – 1.40 1.60 –0.38 2.34 –0.69 0.10 –0.03 19.3 –7.3
30mg Single dose 5.17 – 0.93 5.29 – 0.98 2.38 –0.32 2.25 –0.42 0.10 –0.02 18.5 –2.6
Repeated dose 5.06 – 0.89 5.24 – 0.94 2.48 –0.48 2.52 –0.51 0.10 –0.02 21.0 –4.1
60mg Single dose 11.25 –3.42 11.59 –3.62 4.54 –0.90 2.57 –0.32 0.09 –0.03 20.7 –6.5
a Values are given as means – standard deviations.
AUC = area under the plasma concentration-time curve; AUCt =AUC during a dosage interval at steady state; AUC¥ =AUC from time zero to
infinity; CL = total plasma drug clearance; Cmax =maximum plasma drug concentration; t½ =elimination half-life; Vd= volume of distribution.
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Fig. 2. Plots of the mean plasma concentration-time curves of in-
travenous edaravone for the three dose groups (20, 30, and 60mg)
on the first day after a single dose, and on the fifth day after repeated
twice-daily doses of 30mg. Values are given as means – standard
deviations.
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Data and Statistical Analyses
The results are expressed as means – standard
deviations. The area under the plasma concentration-
time curve (AUC), elimination half-life (t½), volume
of distribution (Vd), and total plasma drug clearance
(CL) were obtained by noncompartmental anal-
ysis, utilizing the pharmacokinetic analysis pack-
age DAS 2.0 (Drug And Statistics, Shanghai
University of Traditional Chinese Medicine,
Shanghai, China). Statistically significant differ-
ences in the mean values between the different
dosage groupswere determined by one-way analysis
of variance (ANOVA) with an unpaired two-tailed
heteroscedastic t-test. The paired t-test was utilized
to compare the AUC during a dosage interval
(AUCt), AUC from time zero to infinity (AUC¥),
maximum plasma drug concentration (Cmax), t½,
CL, and Vd values for single and multiple dosing.
Statistical significance was set at p < 0.05.
Results
Area under the Plasma Concentration-Time
Curve Values and Maximum Plasma Drug
Concentration Values of Edaravone
in Plasma
The mean AUCt, AUC¥, Cmax, t½, CL, and
Vd values for the three groups after single and
repeated doses are shown in table II. There were
no significant differences between the three groups,
regardless of the number of doses received. The
meanAUC¥ ratio andmeanCmax ratio formultiple-
dose/single-dose administration of 30mg were
0.99 and 1.04, respectively. These values indicate
that there was no accumulation after repeated
doses. The mean plasma concentration-time curves
after single and repeated doses are shown in figure 2.
As shown in the linear equation and the scatter
diagrams (table III and figure 3, respectively), the
Table III. Relationships of edaravone doses to log-normal maximum plasma concentration (ln Cmax) and log-normal area under the plasma
concentration-time curve (ln AUCT) values during a dosage interval at steady state
Parameter Relationship R p-Value Linear correlation
ln Cmax ln Cmax =0.025D +6.918 0.911 0.000 Significant
ln AUCt ln AUCt =0.028D + 11.728 0.865 0.000 Significant
D =dose; R = adjusted R square value.
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Fig. 3. Scatter diagrams of the relationship between the dose and
(a) the log-normal maximum plasma drug concentration (ln Cmax);
and (b) the log-normal area under the plasma concentration-time
curve during a dosage interval (ln AUCt).
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Cmax and AUCt values in the three single-dose
groups appeared linear in accordancewith the doses.
Safety Results
Edaravone, given by intravenous infusion, was
well tolerated at doses of up to 60mg administered
once or 30mg administered twice daily for 5 days.
No symptomatic adverse effects were observed.
Although some laboratory test abnormalities
were observed, the symptoms were mild and tol-
erable, and were considered not to diminish the
value of the study. All serum biochemistry indices
returned to normal levels after 7 days, without any
treatment. All adverse events were possibly related
to the drug. The changes in serum biochemistry in
subjects who experienced adverse events and the
numbers of adverse events that occurred after single
or multiple doses are shown in table IV.
Discussion and Conclusion
Edaravone has been widely used clinically in
Japan. It has been reported that the binding rate
of 14C-MCI-186 to human serum protein is 91.0–
91.9%.[21] After precipitation of plasma protein
by perchloric acid, edaravone shows good line-
arity in the sample, thus it is unnecessary to add
an internal standard. In our study, we also car-
ried out relevant research on edaravone metabo-
lism in the human body, but we could not detect
the accurate concentration of edaravone in urine,
because of impurity interference. An isotope-
labeling method was used to determine the con-
centration of edaravone in urine, but it could only
be used to measure the urinary concentrations
during the first 2 hours.[20] This is consistent with
the results of our study. Edaravone is excreted as
the unmetabolized drug (~1%) or is metabolized
by sulfation (5–13%) or glucuronidation (68–83%)
and excreted in urine within 24 hours of admin-
istration.[22] There were no significant differences
between the multiple-dose group and the single-
dose groups, indicating that there was no accu-
mulation after multiple administrations.
In our study, we observed that edaravone dis-
played a linear increase in the Cmax and AUCt
values over a dose range of 20–60mg admin-
istered by intravenous infusion. The Cmax values
were measured 30 minutes after the intravenous
infusion of edaravone. The Cmax values (table II)
were significantly higher than the values reported
in a previous study (Cmax 222.53 – 16.77 ng/mL,
dosage 0.2mg/kg; Cmax 658.89 – 96.88 ng/mL,
dosage 0.5mg/kg; Cmax 1727.19 – 210.88 ng/mL,
dosage 1.0mg/kg; andCmax 3060.73– 236.88 ng/mL,
dosage 1.5mg/kg).[20] The related explanations
are as follows:
1. The intravenous infusion time in our study
was 30 minutes, while in the previous study it was
40 minutes.
2. We developed a simple, rapid, sensitive method
for determination of the edaravone plasma con-
centrationwithHPLC,which took less than 10min-
utes to obtain the supernatant, making it more
convenient and stable. Edaravone is unstable in
human plasma in air,[23] and the extraction method
always takes more than 30 minutes, meaning that
edaravone is exposed to air for a long time.[20]
3. In a preliminary experiment, we found that
edaravone in human plasma was unstable when
stored at room temperature for more than
Table IV. Changes of serum biochemistry in subjects with adverse events after single or multiple doses of edaravone parenteral solution
Serum biochemistry parameter Normal
range
Subject
identifier
Dosage group Value prior to
administration
Value after
administration
Triacylglycerol (mmol/L) 0.45–2.25 S1B 20mg (single dose) 2.06 3.80
M2G 30mg (multiple dose) 1.65 2.88
White blood cell count (·109/L) 4.0–10.0 S1D 20mg (single dose) 5.0 3.5
M2H 30mg (multiple dose) 4.0 3.8
Alanine transaminase (U/L) 0.0–45.0 S1H 20mg (single dose) 10.2 65.6
S3I 60mg (single dose) 10.4 70.1
Creatinine (mmol/L) 44.0–136.0 M2J 30mg (multiple dose) 50.6 39.7
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45 minutes.[24] This was consistent with the dra-
matic decrease in the edaravone plasma concen-
tration. Thus we tested all plasma samples within
24 hours after administration of the drug.
The LC-MS/MSmethod, as another analytical
method for measuring the plasma edaravone con-
centration, has also been used by another group.
The calibration curve is linear in the range of
10–500ng/mL but is not linear above 500ng/mL.[19]
In conclusion, edaravone parenteral solution
is both well tolerated and safe when administered
as a single dose or as multiple doses.
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